Vaccinal prevention of pneumococcal infection in risk groups: current clinical guidelines
https://doi.org/10.30629/0023-2149-2024-102-1-62-68
Abstract
Pneumococcal infection is a serious problem for practical healthcare. After the COVID-19 pandemic, there has been a significant increase in bacterial infections incidence, with pneumococcus remaining the main causative agent in all age groups. Among military personnel, pneumococcal pneumonia is the most common severe pathology requiring significant efforts in patient treatment. Vaccination remains an important factor in reducing the incidence of disease, and most importantly, in significant reduction of cases of invasive pneumococcal infection, which is characterized by high mortality. Currently, modern approaches to vaccination regimens in adults have been developed, which are reflected in this publication.
About the Authors
A. A. Zaitsev
Main Military Clinical Hospital named after academician N.N. Burdenko of the Ministry of Defense of Russia; Medical Institute of Continuing Education of «Russian Biotechnology University (ROSBIOTECH)»; Central Research Institute of Epidemiology of Rospotrebnadzor
Russian Federation
Russian Federation
Andrey A. Zaitsev — Doctor of Medical Sciences, Professor, Chief Pulmonologist of the Ministry of Defense of Russia, Chief Pulmonologist
Moscow
N. I. Briko
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Nikolai I. Briko — Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences, Head of the Department of Epidemiology and Evidence-Based Medicine (EBM)
Moscow
V. G. Akimkin
Central Research Institute of Epidemiology of Rospotrebnadzor
Russian Federation
Russian Federation
Vasily G. Akimkin — Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences, Director
Moscow
I. V. Shubin
Pirogov Russian National Research Medical University (Pirogov Medical University) of the Ministry of Health of Russia
Russian Federation
Russian Federation
Igor V. Shubin — Doctor of Medical Sciences
Moscow
References
1. Sinopalnikov A.I., Zaitsev A.A. Analysis of the state of pulmonological care in the Armed Forces and ways to improve it. Military Medical Journal. 2008;8:31–40. (In Russian).
2. Zaitsev A.A. Epidemiology of respiratory diseases in military personnel and directions for improving pulmonological care. Military Medical Journal. 2018;11:4–9. (In Russian).
3. Kuchmin A.N., Akimkin V.G., Sinopalnikov A.I., et al. Diagnosis, treatment and prevention of community-acquired pneumonia in military personnel of the Ministry of Defense of the Russian Federation. Guidelines. Moscow, 2010. (In Russian).
4. Avdeev S.N. et al. Community-acquired pneumonia: federal clinical guidelines for diagnosis and treatment. Pulmonology. 2022;32(3):295–355. (In Russian). DOI: 10.18093/0869-0189-2022-32-3-295-355
5. Avdeev S.N., Beloborodov V.B., Belotserkovsky B.Z. Severe community-acquired pneumonia in adults. Clinical recommendations of the Federation of anesthesiologists and resuscitators of Russia. Anesthesiology and resuscitation. 2022;1:6–35. (In Russian). DOI: 10.17116/anaesthesiology20220116
6. Chuchalin A.G., Briko N.I., Avdeev S.N. et al. Federal clinical guidelines for the vaccination of pneumococcal infection in adults. Pulmonology. 2019;29(1):19–34. (In Russian). DOI: 10.18093/0869-0189-2019-29-1-19-34
7. Baranov A.A., Namazova-Baranova L.S., Briko N.I., Chuchalin A.G. Vaccinal prophylaxis of pneumococcal infection. Federal Clinical Guidelines of the Union of Pediatricians of Russia. Moscow, 2015:24. (In Russian). DOI: 10.15690/pf.v12i5.1457
8. Zaitsev A.A., Akimkin V.G., Briko N.I., Kryukov E.V., Shubin I.V., Antipushina D.N., Sergeeva N.V. Epidemiology and vaccination of pneumococcal infections in military personnel. Military Medical Journal. 2019;340(1):39–45. (In Russian).
9. Guchev I.A., Klochkov O.I., Sinopalnikov A.I. Prevention of outbreaks of community-acquired pneumonia with polysaccharide pneumococcal vaccine: an analysis of the prospects for application for law enforcement agencies in Russia. Antibiotics and chemotherapy. 2016;61(1–2):43–52. (In Russian).
10. Zhogolev S.D., Ogarkov P.I., Efimov E.I. et al. The development of the epidemic process of community-acquired pneumonia among military personnel. Vestn. Ros. military-med. acad. 2008;2(22):269–270. (In Russian).
11. Russell K., Baker C. et al. Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: A randomized, double-blind, placebo-controlled trial. Vaccine. 2015;33(9):1182–1187. DOI: 10.1016/j.vaccine.2014.12.058
12. Levine H., Balicer R., Zarka S. et al. Dynamics of pneumococcal acquisition and carriage in young adults during training in confined settings in Israel. PLoS One. 2012;7(10):e46491. DOI: 10.1371/journal.pone.0046491
13. Kozlov R.S., Avdeev S.N., Briko N.I. et al. Vaccine prevention of pneumococcal infections in adults. resolution of the Council of Experts (Moscow, December 16, 2017). Clinical microbiology and antimicrobial chemotherapy. 2018;20(1):5–8. (In Russian). DOI: 10.36488/cmac.2018.1.5-8
14. Falkenhorst G., Remschmidt C., Harder T. et al. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0169368. DOI: 10.1371/journal.pone.0169368
15. Vaccination of adults with bronchopulmonary pathology. A guide for physicians. Ed. M.P. Kostinov. M., 2013:112. (In Russian).
16. Order of the Ministry of Health of the Russian Federation of December 6, 2021 N 1122n “On approval of the national calendar of preventive vaccinations, the calendar of preventive vaccinations for epidemic indications and the procedure for conducting preventive vaccinations.” (In Russian). [Electronic resource]. URL: https://www.garant.ru/products/ipo/prime/doc/403158640/?ysclid=ljwp1jtabu453172325
17. Gonzalez-Romo F., Picazo J., Rojas A. et al. Consensus document on pneumococcal vaccination in adults at risk by age and underlying clinical conditions. [2017 Update]. Rev. Esp. Quimioter. 2017;30(2):142–168.
18. Australian Government Department of Health. Australian immunisation handbook. The National Immunisation Program. [Electronic resource]. URL: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/national-immunisation-program-schedule
19. Center for disease control and prevention. Pneumococcal diseases. Pneumococcal Vaccination. [Electronic resource]. URL: https://www.cdc.gov/pneumococcal/vaccination.html
20. Tin Tin Htar M., Stuurman A., Ferreira G., et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS One. 2017;12(5):e0177985. DOI: 10.1371/journal.pone.0177985
21. McLaughlin J., Jiang Q., Isturiz R. et al. Effectivenessof 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: A test-negative design. Clin. Infect. Dis. 2018;67(10):1498–1506. DOI: 10.1093/cid/ciy312
22. U.S. National Library of Medicine. Evaluation of the safety and immunogenicity of sequential administration of prevnar 13™ and pneumovax™ 23 in healthy participants 50 years of age and older (V110-029). clinicaltrials.gov NCT02225587. August 26, 2014.
23. Diagnosis, treatment and vaccination of community-acquired pneumonia in military personnel. Guidelines for the treatment of community-acquired pneumonia in military personnel. GVKG named after N.N. Burdenko. Moscow, 2015. (In Russian).
Review
For citations:
Zaitsev A.A., Briko N.I., Akimkin V.G., Shubin I.V. Vaccinal prevention of pneumococcal infection in risk groups: current clinical guidelines. Clinical Medicine (Russian Journal). 2024;102(1):62-68. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-1-62-68
Views:
403
Email this article 